Dpp-Iv Inhibitor Combined With A Further Antidiabetic Agent, Tablets Comprising Such Formulations, Their Use And Process For Their Preparation

Patent No. EP2285410 (titled "Dpp-Iv Inhibitor Combined With A Further Antidiabetic Agent, Tablets Comprising Such Formulations, Their Use And Process For Their Preparation") was filed by Boehringer Ingelheim on Apr 2, 2009. The application was issued on Sep 26, 2018.

Patent Summary

Patent Family

Patent Family

Patent Oppositions (4)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ISARPATENTJun 26, 2019ISARPATENT
GALENICUM HEALTH SLUJun 25, 2019TORREJON NIETO
HEXALJun 25, 2019ELKINGTON AND FIFE
HGFJun 25, 2019-

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2285410

BOEHRINGER INGELHEIM
Application Number
EP09728065A
Filing Date
Apr 2, 2009
Status
Revoked
Nov 11, 2022
Publication Date
Sep 26, 2018